YK Bioventures

Investment decisions are made by co-founders Michael Chen and Timothy Lu, who serve as managing partners. Both hold active academic appointments — Chen at Stanford in bioengineering and Lu at MIT in biological engineering. The firm operates without a large investment committee structure, allowing the partners to move quickly on early-stage scientific opportunities they evaluate directly.

The firm sources deal flow primarily through the founders' academic networks at Stanford, MIT, and affiliated institutions. Both principals actively publish and peer-review in synthetic biology and CRISPR-related fields, giving them early visibility into lab-stage discoveries. This embedded model allows the firm to engage with scientific teams before they formally seek venture funding, often leading to pre-seed rounds where traditional firms are absent.

YK Bioventures concentrates on pre-seed and seed-stage investments, with initial checks typically between $500,000 and $2 million. The firm occasionally participates in Series A and B follow-on rounds for existing portfolio companies when syndicate dynamics allow. Its thesis is built on engaging with companies at the point of highest scientific risk, before clinical validation is established.

YK Bioventures is structured as a traditional venture capital partnership, not a single family office. Its capital comes from the founders and a network of high-net-worth individuals from the biotechnology and technology sectors. The firm does not publicly disclose a formal limited partner structure or institutional fundraising vehicle.

YK Bioventures has not publicly stated sector exclusions, but its disclosed portfolio demonstrates a tight focus on therapeutics enabled by synthetic biology, AI-driven drug discovery platforms, and digital health infrastructure. The firm does not appear to invest in medical devices, healthcare services delivery, or later-stage biotechnology companies where clinical risk has been substantially retired.

YK Bioventures concentrates exclusively on direct equity investments in operating companies. There is no public evidence of the firm making fund commitments to other venture managers or participating as a limited partner in third-party funds. This aligns with its operator-investor model, where the principals' scientific expertise is applied directly to company formation and governance.

YK Bioventures actively co-invests alongside larger venture firms, as demonstrated in rounds where it has syndicated with Andreessen Horowitz and Pillar VC. The firm leads or co-leads seed financings and participates in broader syndicates for follow-on rounds. Its Beijing office, established in 2023, suggests an increasing openness to cross-border co-investment structures for portfolio companies pursuing clinical operations in China.